Clinical Trial Update: The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS) [NA]

View source ↗

Summary

The EMPRESS trial evaluating the EMPrint Ablate and RESect System for metastatic lung tumors has completed and results have been posted. Sponsor: Medtronic (MIT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• EMPrint Ablate and RESect System

Snippet

Sponsor: Medtronic - MITG | Conditions: Lung Cancer | NA | Status: COMPLETED | Results posted: 2018-04-05